Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host

Hugues de Lavallade,1 Paula Garland,2* Takuya Sekine,1* Katja Hoschler,3 David Marin,1 Kate Stringaris,1 Eva Loucaides,1 Katherine Howe,1 Richard Szydlo,1 Ed Kanfer,2 Donald Macdonald,2 Peter Kelleher,4 Nichola Cooper,2 Ahmad Khoder,1 Ian H. Gabriel,1 Dragana Milojkovic,2 Jiri Pavlu,2 John M. Goldman,1 Jane F. Apperley,1 and Katayoun Rezvani1

1Department of Haematology, Imperial College, London; 2Department of Haematology, Imperial College Healthcare NHS Trust, London; 3Respiratory Virus Unit, Health Protection Agency Centre for Infections, London, and 4Department of Immunology, Chelsea and Westminster Hospital, Imperial College Healthcare NHS Trust, London, UK


Online Supplementary Figure S1. Fluorescent activated cell sorting (FACS) plots from three patients: one from each group- an allogeneic stem cell transplant recipient (Allo-SCT) a patient with a B-cell malignancy (CLL) and a patient with chronic myeloid leukemia (CML) - and a control with robust T-cell responses to H1N1 vaccine. Cells were gated on CD3+ lymphocytes. The Y axis represents CD8 expression and the X axis represents TNFα + INFγ production. The allo-SCT patient (upper left panel), CLL patient (lower left panel) and the healthy control (lower right panel) received both the 2009 H1N1 vaccine and the 2009/2010 seasonal influenza vaccine, while the CML patient (upper right panel) was only vaccinated with the 2009 H1N1 vaccine.